Close Menu

A*Star

The assay underwent clinical validation at three centers in Singapore and 5,248 patients were ultimately screened using the test.

The Singapore-based immune profiling firm aims to open a US facility by the end of the year and begin running projects out of it in the first quarter of 2021.

The Singapore-based company will use the funds to expand its presence in the US and develop its platform, which uses mass cytometry to profile T-cell response.

Avatamed will use the funds to expand into the Asia-Pacific market and set up a lab in Singapore to provide precision cancer drug screening services.

The alliance, led by Singapore-based startup Proteona, also includes several organizations from that city state as well as German research institutes.

The effort is focused on building an atlas of immune cell types found across a range of Asian population groups as part of the Human Cell Atlas project.

A*STAR and Tan Tock Seng Hospital developed the test, which is the first diagnostic to be deployed in the country's hospitals since the outbreak began in December.

Researchers in Singapore found fewer genetic alterations in tumors from East Asians than Europeans and identified a gene expression subtype specific to East Asians.

For the first phase of the SG10K project, researchers sequenced thousands of Chinese, Malay, or Indian individuals from Singapore, uncovering new variants and population insights.

The company's goal is to serve what it sees as a massive but underaddressed target group: Asian women.

Pages

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.